The CEO's 10b5-1 plan was adopted six months ago, so the filing does not signal a near-term negative catalyst. However, the absence of insider buying and the ongoing plan sales warrant monitoring for any change in the company's operational trajectory or upcoming earnings. The sale is small relative to market cap and likely part of routine portfolio diversification.
Price Chart
Executive Summary
CEO Derek Maetzold filed a Form 144 on June 1, 2026, to sell 14,008 shares of Castle Biosciences common stock, with an estimated aggregate market value of approximately $293,748. The sale is part of a Rule 10b5-1 trading plan adopted on December 3, 2025, covering shares held by Maetzold and related family trusts. While the CEO's intent to sell is notable, the plan was established six months ago, reducing the timing signal.
Key Facts
- CEO Derek Maetzold intends to sell 14,008 shares via Form 144.
- Estimated aggregate market value of the proposed sale is approximately $293,748.
- Sale is under a Rule 10b5-1 trading plan dated December 3, 2025.
- Shares are being sold through Goldman Sachs & Co. LLC.
- The plan covers shares from Maetzold directly and multiple family trusts.
- Company market cap is approximately $639 million; the sale represents ~0.05% of market cap.
- No recent insider buying activity was reported in the prior 30 days.
Financial Impact
Proposed sale of ~$294K worth of CSTL common stock, representing about 0.05% of the company's $639M market cap.
Risk Factors
- CEO selling under a pre-arranged plan may still be perceived negatively by the market if sentiment is fragile.
- Continued insider selling without buying could signal lack of confidence in near-term prospects.
- The 10b5-1 plan does not preclude additional unplanned sales, which would be more concerning.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001958244-26-000337 |
| Document: 0001958244-26-000337-index.html | 0001958244-26-000337 |
| Document: 0001958244-26-000337.txt | 0001958244-26-000337 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Insider Cluster | $33.19 $33.08 | ▼ −0.33% | ▲ +0.19% | $33.38 (+0.57%) |
Oct 5, 2026 21d ago | 144 | $33.36 $33.00 | ▼ −1.08% | ▼ −0.84% | $33.38 (+0.06%) |
Oct 5, 2026 21d ago | Insider Cluster | $33.36 $33.00 | ▼ −1.08% | ▼ −0.84% | $33.38 (+0.06%) |
Sep 23, 2026 4w ago | Insider Cluster | $35.19 $35.81 | ▼ −1.76% | ▼ −1.22% | $33.38 (+5.14%) |
Sep 16, 2026 5w ago | Insider Cluster | $36.78 $35.34 | ▼ −3.92% | ▼ −4.04% | $33.38 (−9.24%) |
Sep 11, 2026 6w ago | 144 | $33.44 $35.50 | ▲ +6.16% | ▲ +6.62% | $33.38 (−0.18%) |
Sep 3, 2026 7w ago | Insider Cluster | $32.91 $32.76 | ▲ +0.46% | ▼ −0.09% | $33.38 (−1.43%) |
Sep 2, 2026 7w ago | Insider Cluster | $32.65 $32.91 | ▲ +0.80% | ▲ +1.18% | $33.38 (+2.24%) |
Sep 1, 2026 7w ago | Insider Cluster | $33.42 $32.65 | ▼ −2.30% | ▼ −3.35% | $33.38 (−0.12%) |
Aug 27, 2026 8w ago | Insider Cluster | $33.50 $33.03 | ▼ −1.40% | ▼ −1.10% | $33.38 (−0.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers